ProfileGDS5678 / 1456611_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 66% 60% 66% 66% 68% 61% 66% 68% 70% 72% 66% 66% 67% 66% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 14.0234266
GSM967853U87-EV human glioblastoma xenograft - Control 23.5747660
GSM967854U87-EV human glioblastoma xenograft - Control 34.0252466
GSM967855U87-EV human glioblastoma xenograft - Control 43.9976266
GSM967856U87-EV human glioblastoma xenograft - Control 54.1372568
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.7285361
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 24.0072866
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 34.1626768
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 44.3456670
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 14.6155672
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 23.9913366
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 34.0131366
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 44.0894167
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 54.012766